As the number of cell and gene therapies expands, it's increasingly important for long-term patient data, explained Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health.
Fran Gregory, PharmD, MBA
Advertisement
Fran Gregory, PharmD, MBA, is the vice president of emerging therapies at Cardinal Health.
Articles by Fran Gregory, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Upadacitinib Label for Treating Inflammatory Bowel Disease
2
Experts, Patients Highlight Barriers to Arthritis Care Amid World Arthritis Day Observance
3
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
4
Medical School Diversity Declines Following Affirmative Action Repeal
5
